THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014
AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
31 May 2024
Graft Polymer (UK)
Plc
("Graft Polymer" or the
"Company")
Further Patent
Application
Filing of US Provisional
Patent for Treatment of Mental Health Disorders
Graft Polymer (UK) Plc (LSE: GPL)
announces that it has filed a second utility patent application
(provisional) with the United States Patent and Trademark Office
(USPTO). This application is for the use of the Company's
proprietary and patented self-nanoemulsifying drug delivery systems
(SNEDDS) platform for the delivery of drugs for the treatment of
mental health disorders such as Generalised Anxiety Disorder (GAD),
Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder
(PTSD).
Patent Filing Overview
The provisional patent application,
titled 'Composition and methods
for mental health disorders using a self-nanoemulsifying drug
delivery systems (SNEDDS)', covers the innovative
application of Graft Polymer's SNEDDS platform to enhance the
bioavailability, pharmacokinetics and stability of therapeutics
used in the treatment of health disorders such as GAD, MDD and
PTSD, many of which have poor solubility leading to suboptimal drug
delivery and posing an obstacle to successful formulation. This
approach aims to leverage the Company's existing advanced
biopolymer expertise to address significant unmet medical needs in
addiction therapy.
Strategic Significance
The filing of this patent follows
the announcement, by the Company, on 28 May 2024 relating to the
filing of a similar utility patent application (provisional) for
the treatment of substance use disorders. It marks further progress
in the Company's strategic focus on the healthcare industry,
following the disposal of its industrial plastic manufacturing
unit, Graft Polymer D.O.O, as announced on 3 May 2024. This
disposal has enabled the Company to focus its attention and
resources on its Graft Bio division, which represents, in the
Directors' opinion, strong prospectivity through its
intellectual property (IP), licensing agreements, and sales
contracts.
Anthony Tennyson, CEO commented:
"We are delighted to announce
further progress in leveraging our existing biopolymer intellectual
property for additional important healthcare applications with
substantial unmet medical needs."
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director
Email: yifat@graftpolymer.com
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner
(Corporate Finance)
Guy McDougall
(Sales)
+44 (0) 20
3328 5656